A consensus-based guideline for personalized bacteriophage therapy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Guidelines for Tailored Bacteriophage Therapy Based on Expert Consensus

  • By

  • Silvia Würstle

  • Simone C. Lieberknecht-Jouy

  • Anja Düchting

  • Holger Lößner

  • Pieter-Jan Ceyssens

  • Jean-Paul Pirnay

  • Mathieu de Jode

  • Shawna McCallin

  • Lorenz Leitner

  • Christian Willy

  • Sebastian Leptihn

  • Imke Korf

  • Evgeny A. Idelevich

  • Martin Witzenrath

  • Timo Faltus

  • Peter Ruth

  • Henning Blume

  • Manuel Cornely

  • Helmut Fickenscher

  • Mathias W. Pletz

  • Sylvia Hafkemeyer

  • Christine Rohde

  • Oleg Krut

  • Wolfgang Beyer

  • Oliver Hartwich

  • Ulrich Matt

  • Rebecca L. Knoll

  • Münevver Demir

  • Jens Hammerl

  • Stefanie Barbirz

  • Mirjam Stahl

  • Renate Krüger

  • Joachim Bugert

  • Melanie Kempe

  • Paul E. Turner

  • Benjamin Chan

  • Tristan Ferry

  • Maria J. G. T. Vehreschild

  • Annika Y. Classen

  • September 21, 2026

Share

Clinical Scorecard: Guidelines for Tailored Bacteriophage Therapy Based on Expert Consensus

At a Glance

CategoryDetail
ConditionBacterial infections
Key MechanismsUtilization of bacteriophages as targeted therapy against antibiotic-resistant bacteria.
Target PopulationAdults and children with bacterial infections, particularly those with antimicrobial resistance.
Care SettingClinical settings involving infectious disease management and antimicrobial stewardship.

Key Highlights

  • Guidelines provide consensus-based recommendations for personalized phage therapy.
  • Developed by an interdisciplinary expert group including clinicians and patient representatives.
  • Focus on practical application in real-world clinical settings.
  • Addresses quality control and clinical administration of phage therapy.
  • Guidelines are applicable internationally and endorsed by key medical societies.

Guideline-Based Recommendations

Diagnosis

  • Assess bacterial infections where conventional antimicrobial options have failed.

Management

  • Implement personalized phage therapy based on individual patient needs and bacterial susceptibility.

Monitoring & Follow-up

  • Regularly evaluate the effectiveness and safety of phage therapy in clinical practice.

Risks

  • Consider potential biological and regulatory complexities associated with phage therapy.

Patient & Prescribing Data

Patients with bacterial infections resistant to standard antibiotics.

Phage therapy should be considered as a last-resort treatment option.

Clinical Best Practices

  • Follow established guidelines for phage preparation and quality control.
  • Engage in interdisciplinary collaboration for effective implementation of phage therapy.
  • Ensure informed consent and patient advocacy involvement in treatment decisions.

Related Resources & Content

Original Source(s)

A consensus-based guideline for personalized bacteriophage therapy

  • by Silvia Würstle, Simone C. Lieberknecht-Jouy, Anja Düchting, Holger Lößner, Pieter-Jan Ceyssens, Jean-Paul Pirnay, Mathieu de Jode, Shawna McCallin, Lorenz Leitner, Christian Willy, Sebastian Leptihn, Imke Korf, Evgeny A. Idelevich, Martin Witzenrath, Timo Faltus, Peter Ruth, Henning Blume, Manuel Cornely, Helmut Fickenscher, Mathias W. Pletz, Sylvia Hafkemeyer, Christine Rohde, Oleg Krut, Wolfgang Beyer, Oliver Hartwich, Ulrich Matt, Rebecca L. Knoll, Münevver Demir, Jens Hammerl, Stefanie Barbirz, Mirjam Stahl, Renate Krüger, Joachim Bugert, Melanie Kempe, Paul E. Turner, Benjamin Chan, Tristan Ferry, Maria J. G. T. Vehreschild, Annika Y. Classen

  • September 21, 2026

Related Content

How HCPs can help students stay healthy at school

"We are at risk as a nation of losing our measles elimination status."

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

Global reach and sustained engagement of a structured digital education program in medical mycology: an observational analysis of the 2025 ESCMID-EFISG webinar series